Cibus, Inc.

NASDAQ:CBUS

Biotechnology

Healthcare
$1.37 +3.10%

+$0.04 today

Market cap
$104.71M
Beta
1.65
P/E (TTM)
-8.6
EPS (TTM)
-$0.16
52W Low $1.09High $4.19

Volume 0.25M

Average 0.51M

CBUS Long-term Debt

Borrowings due after more than one year.

Cibus, Inc.NASDAQ: CBUS

Long-term Debt · Q1 FY2026 · quarter ended Mar 2026

Long-term debt rises 135520.6% from a year ago

Long-term debt stood at $244.12M at the end of Q1 FY2026, up 135520.6% from a year earlier and up 3.9% from the prior quarter.

Context

  • Long-term debt amounted to 75.3% of total assets at the end of Q1 FY2026, up 75.2 pp from a year earlier.
  • Long-term debt increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether long-term debt keeps rising in the next quarterly balance sheet after a +135520.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$244.12M+3.9% QoQ
Last fiscal yearDec 2025
$235.02M+103889.4% YoY
Year agoMar 2025
$180K+135520.6% since
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+135520.6%——
1 year+103889.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Long-term Debt history

USD · from the balance sheet

Latest · FY2025
235.02M USD
Year-over-year change
+103889.4%

Long-term Debt vs competitors

How CBUS compares with its peers on the latest reported figures

  • CBUS's Mar 2026 long-term debt of $244.12M is the highest of the 10 companies compared; the peer median is $0.
  • Long-term debt amounts to 75.3% of total assets for CBUS, versus a peer median of 0.0%.
CBUS Competitors Peer median
Long-term Debt for CBUS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CBUSCibus, Inc.Mar 2026$244.12M +135520.6%—75.3%
CAMPCAMP4 Therapeutics CorporationMar 2026$1.74M ——1.6%
ACRVAcrivon Therapeutics, Inc. Common StockMar 2026$1.26M ——1.2%
UNCYUnicycive Therapeutics, Inc.Mar 2026$217K ——0.3%
RLMDRelmada Therapeutics, Inc.Mar 2026$0 ——0.0%
IMUXImmunic, Inc.Mar 2026$0 ——0.0%
VXRTVaxart, Inc.Mar 2026$0 ——0.0%
MNOVMediciNova, Inc.Mar 2026$0 ——0.0%
PMVPPMV Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
BMEABiomea Fusion, Inc.Mar 2026$0 ——0.0%
Peer median (excluding CBUS) $0——0.0%

Competitors are the stored peer set for CBUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents13.82M3.43M32.7M14.43M9.92M
Short-term Investments00000
Net Receivables00530K1.04M703K
Inventory00000
Other Current Assets499K705K1.99M1.47M1.44M
Total Current Assets15.18M4.13M35.22M16.95M12.07M
Property, Plant & Equipment (Net)21.73M18.13M37.46M44.69M27.86M
Goodwill00434.9M253.47M232.52M
Intangible Assets0158K35.41M33.58M31.68M
Long-term Investments00000
Tax Assets00000
Other Non-current Assets282K01.42M1.39M926K
Total Non-current Assets22.01M18.29M509.19M333.12M292.98M
Total Assets37.19M22.42M544.41M350.07M305.05M
Account Payables1.26M340K6.13M5.96M8.07M
Short-term Debt00833K436K3.17M
Tax Payables00000
Deferred Revenue0107K1.21M932K536K
Other Current Liabilities2.71M403K5.29M5.87M5.09M
Total Current Liabilities4.85M1.66M21.32M19.88M16.86M
Long-term Debt00536K226K235.02M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities702K79K167.12M200.91M1.56M
Total Non-current Liabilities18.21M13.53M184.79M232.36M266.36M
Total Liabilities23.06M15.19M206.12M252.24M283.22M
Common Stock4K5K8K9K79K
Retained Earnings(196.09M)(212.15M)(479.78M)(731.17M)(858.25M)
Accumulated OCI008K15K39K
Other Stockholders Equity00000
Minority Interest0044.82M5.67M0
Total Equity14.13M7.23M338.29M97.83M21.83M
Total Debt17.88M13.91M24.62M36.29M267.96M
Net Debt4.05M10.48M(8.08M)21.85M258.04M

Cibus, Inc.

NASDAQ:CBUS

Intrinsic Alpha fair value

Locked

Current Price

$1.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.